MEDP logo

MEDPACE HOLDINGS INC

MEDPNASDAQ
๐Ÿ† #512 by market capEarnings Oct 28US Equity
$605.50โ–ฒ $3.09 (+0.51%)
๐ŸŒ™ After hours$605.50โ–ฒ 0.00%Regular close ยท extended-hours price shown
1hโ€”
24hโ–ฒ 0.5%
7dโ–ฒ 3.0%
14dโ–ฒ 3.4%
30dโ–ฒ 14.3%
1yโ–ฒ 31.7%
๐ŸฆMarket Cap
$16.90B
Mid Cap
๐Ÿ“ˆRevenue Growth (YoY)
+24.7%
Healthy
๐Ÿ“ŠGross Margin
28.8%
Moderate
๐Ÿ’ตFCF Margin
25.4%
Strong
โš–๏ธP/S Ratio
6.0x
Fair
Otter Score
52
Weak

Trading Snapshot

Day Range
$603.09 โ€“ $611.03
52-Week Range
$373.00 โ€“ $677.90
Volume
$3.08B
Avg Volume
$3.54B
Shares Outstanding
27.9M
Next Earnings
Oct 27, 2026

Fundamentals Snapshot

Annual Revenue
$2.53B
Last Q Revenue
$707M
P/E Ratio
34.2
P/S Ratio
6.0x
EPS (TTM)
$17.05
Dividend Yield
โ€”

Why Investors Own MEDP

  • โœ“High-growth profile โ€” revenue up +34.0% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 63% gross margin and 29% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$2.53Bโ–ฒ +39.4% YoY
Gross Margin (TTM)
63.1%โ–ฒ +4.2% YoY
Operating Income (TTM)
$541Mโ–ฒ +39.4% YoY
Free Cash Flow (TTM)
$739Mโ–ฒ +39.4% YoY

About MEDPACE HOLDINGS INC

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
52/100

Analyst Ratings

โ“˜
Consensus
Hold
20 analysts
Strong Buy2
Buy5
Hold12
Sell1
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates